Review



l ala γ d glu mdap tri dap  (InvivoGen)


Bioz Verified Symbol InvivoGen is a verified supplier
Bioz Manufacturer Symbol InvivoGen manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    InvivoGen l ala γ d glu mdap tri dap
    Pre-treatment with NOD1- and NOD2-stimulatory ligands prior to infection with C. trachomatis significantly impacts inclusion size in NLR-expressing cell lines. HepG2, C-33A, and SiHa cells were pre-treated with <t>Tri-DAP,</t> MDP, or both, prior to infection with C. trachomatis L2 strain Bu/434. At 24 hpi, cells were fixed, inclusions were labeled, counted, and measured. zStacks of MOMP-labeled objects were obtained from a Zeiss 700 confocal microscope, and approximate volume measurements were calculated for all inclusions present within 10 imaging fields. Data presented represent all MOMP-labeled objects counted resulting in inclusions > 20 µm 3 ; 3 µm across with red lines indicating the mean of each group within a data set. Significance was assessed via one-way ANOVA with multiple comparisons. ****; P < 0.0001, ***; P < 0.001, **; P < 0.01, ns; not significant.
    L Ala γ D Glu Mdap Tri Dap, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 134 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/l ala γ d glu mdap tri dap/product/InvivoGen
    Average 94 stars, based on 134 article reviews
    l ala γ d glu mdap tri dap - by Bioz Stars, 2026-05
    94/100 stars

    Images

    1) Product Images from "Chlamydia trachomatis restricts signaling through NOD2 until late in the pathogen’s developmental cycle"

    Article Title: Chlamydia trachomatis restricts signaling through NOD2 until late in the pathogen’s developmental cycle

    Journal: Infection and Immunity

    doi: 10.1128/iai.00472-25

    Pre-treatment with NOD1- and NOD2-stimulatory ligands prior to infection with C. trachomatis significantly impacts inclusion size in NLR-expressing cell lines. HepG2, C-33A, and SiHa cells were pre-treated with Tri-DAP, MDP, or both, prior to infection with C. trachomatis L2 strain Bu/434. At 24 hpi, cells were fixed, inclusions were labeled, counted, and measured. zStacks of MOMP-labeled objects were obtained from a Zeiss 700 confocal microscope, and approximate volume measurements were calculated for all inclusions present within 10 imaging fields. Data presented represent all MOMP-labeled objects counted resulting in inclusions > 20 µm 3 ; 3 µm across with red lines indicating the mean of each group within a data set. Significance was assessed via one-way ANOVA with multiple comparisons. ****; P < 0.0001, ***; P < 0.001, **; P < 0.01, ns; not significant.
    Figure Legend Snippet: Pre-treatment with NOD1- and NOD2-stimulatory ligands prior to infection with C. trachomatis significantly impacts inclusion size in NLR-expressing cell lines. HepG2, C-33A, and SiHa cells were pre-treated with Tri-DAP, MDP, or both, prior to infection with C. trachomatis L2 strain Bu/434. At 24 hpi, cells were fixed, inclusions were labeled, counted, and measured. zStacks of MOMP-labeled objects were obtained from a Zeiss 700 confocal microscope, and approximate volume measurements were calculated for all inclusions present within 10 imaging fields. Data presented represent all MOMP-labeled objects counted resulting in inclusions > 20 µm 3 ; 3 µm across with red lines indicating the mean of each group within a data set. Significance was assessed via one-way ANOVA with multiple comparisons. ****; P < 0.0001, ***; P < 0.001, **; P < 0.01, ns; not significant.

    Techniques Used: Infection, Expressing, Labeling, Microscopy, Imaging

    Pre-treatment with NOD2-stimulatory ligands delays the development of C. trachomatis in NLR-expressing cell lines. HepG2 ( A ), C-33A ( B ), and SiHa ( C ) cells were either left untreated or pre-treated with the NOD1-stimulatory ligand Tri-DAP, the NOD2-stimulatory ligand MDP, or both Tri-DAP and MDP. After 24 hours, cells were infected with C. trachomatis , and the development of infectious EBs was assessed at the indicated time points (30, 48, and 72 hpi). Lines delineate the mean of three separate biological replicates with each replicate displayed as a colored dot. Significance was assessed via one-way ANOVA with multiple comparisons. **; P < 0.01, *; P < 0.05, ns; not significant.
    Figure Legend Snippet: Pre-treatment with NOD2-stimulatory ligands delays the development of C. trachomatis in NLR-expressing cell lines. HepG2 ( A ), C-33A ( B ), and SiHa ( C ) cells were either left untreated or pre-treated with the NOD1-stimulatory ligand Tri-DAP, the NOD2-stimulatory ligand MDP, or both Tri-DAP and MDP. After 24 hours, cells were infected with C. trachomatis , and the development of infectious EBs was assessed at the indicated time points (30, 48, and 72 hpi). Lines delineate the mean of three separate biological replicates with each replicate displayed as a colored dot. Significance was assessed via one-way ANOVA with multiple comparisons. **; P < 0.01, *; P < 0.05, ns; not significant.

    Techniques Used: Expressing, Infection



    Similar Products

    l ala γ d glu mdap tri dap  (InvivoGen)
    94
    InvivoGen l ala γ d glu mdap tri dap
    Pre-treatment with NOD1- and NOD2-stimulatory ligands prior to infection with C. trachomatis significantly impacts inclusion size in NLR-expressing cell lines. HepG2, C-33A, and SiHa cells were pre-treated with <t>Tri-DAP,</t> MDP, or both, prior to infection with C. trachomatis L2 strain Bu/434. At 24 hpi, cells were fixed, inclusions were labeled, counted, and measured. zStacks of MOMP-labeled objects were obtained from a Zeiss 700 confocal microscope, and approximate volume measurements were calculated for all inclusions present within 10 imaging fields. Data presented represent all MOMP-labeled objects counted resulting in inclusions > 20 µm 3 ; 3 µm across with red lines indicating the mean of each group within a data set. Significance was assessed via one-way ANOVA with multiple comparisons. ****; P < 0.0001, ***; P < 0.001, **; P < 0.01, ns; not significant.
    L Ala γ D Glu Mdap Tri Dap, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/l ala γ d glu mdap tri dap/product/InvivoGen
    Average 94 stars, based on 1 article reviews
    l ala γ d glu mdap tri dap - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    γ d glu mdap ie dap  (InvivoGen)
    95
    InvivoGen γ d glu mdap ie dap
    Pre-treatment with NOD1- and NOD2-stimulatory ligands prior to infection with C. trachomatis significantly impacts inclusion size in NLR-expressing cell lines. HepG2, C-33A, and SiHa cells were pre-treated with <t>Tri-DAP,</t> MDP, or both, prior to infection with C. trachomatis L2 strain Bu/434. At 24 hpi, cells were fixed, inclusions were labeled, counted, and measured. zStacks of MOMP-labeled objects were obtained from a Zeiss 700 confocal microscope, and approximate volume measurements were calculated for all inclusions present within 10 imaging fields. Data presented represent all MOMP-labeled objects counted resulting in inclusions > 20 µm 3 ; 3 µm across with red lines indicating the mean of each group within a data set. Significance was assessed via one-way ANOVA with multiple comparisons. ****; P < 0.0001, ***; P < 0.001, **; P < 0.01, ns; not significant.
    γ D Glu Mdap Ie Dap, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/γ d glu mdap ie dap/product/InvivoGen
    Average 95 stars, based on 1 article reviews
    γ d glu mdap ie dap - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    synthetic γ d glu mdap  (InvivoGen)
    95
    InvivoGen synthetic γ d glu mdap
    Pre-treatment with NOD1- and NOD2-stimulatory ligands prior to infection with C. trachomatis significantly impacts inclusion size in NLR-expressing cell lines. HepG2, C-33A, and SiHa cells were pre-treated with <t>Tri-DAP,</t> MDP, or both, prior to infection with C. trachomatis L2 strain Bu/434. At 24 hpi, cells were fixed, inclusions were labeled, counted, and measured. zStacks of MOMP-labeled objects were obtained from a Zeiss 700 confocal microscope, and approximate volume measurements were calculated for all inclusions present within 10 imaging fields. Data presented represent all MOMP-labeled objects counted resulting in inclusions > 20 µm 3 ; 3 µm across with red lines indicating the mean of each group within a data set. Significance was assessed via one-way ANOVA with multiple comparisons. ****; P < 0.0001, ***; P < 0.001, **; P < 0.01, ns; not significant.
    Synthetic γ D Glu Mdap, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/synthetic γ d glu mdap/product/InvivoGen
    Average 95 stars, based on 1 article reviews
    synthetic γ d glu mdap - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    ie-dap (a mixture of γ-d-glu-d-mdap and γ-d-glu-l-mdap, chemically synthesized and tested using hek-blue™ nod1)  (Thermo Fisher)
    90
    Thermo Fisher ie-dap (a mixture of γ-d-glu-d-mdap and γ-d-glu-l-mdap, chemically synthesized and tested using hek-blue™ nod1)
    Pre-treatment with NOD1- and NOD2-stimulatory ligands prior to infection with C. trachomatis significantly impacts inclusion size in NLR-expressing cell lines. HepG2, C-33A, and SiHa cells were pre-treated with <t>Tri-DAP,</t> MDP, or both, prior to infection with C. trachomatis L2 strain Bu/434. At 24 hpi, cells were fixed, inclusions were labeled, counted, and measured. zStacks of MOMP-labeled objects were obtained from a Zeiss 700 confocal microscope, and approximate volume measurements were calculated for all inclusions present within 10 imaging fields. Data presented represent all MOMP-labeled objects counted resulting in inclusions > 20 µm 3 ; 3 µm across with red lines indicating the mean of each group within a data set. Significance was assessed via one-way ANOVA with multiple comparisons. ****; P < 0.0001, ***; P < 0.001, **; P < 0.01, ns; not significant.
    Ie Dap (A Mixture Of γ D Glu D Mdap And γ D Glu L Mdap, Chemically Synthesized And Tested Using Hek Blue™ Nod1), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ie-dap (a mixture of γ-d-glu-d-mdap and γ-d-glu-l-mdap, chemically synthesized and tested using hek-blue™ nod1)/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    ie-dap (a mixture of γ-d-glu-d-mdap and γ-d-glu-l-mdap, chemically synthesized and tested using hek-blue™ nod1) - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    l ala γ d glu mdap  (InvivoGen)
    94
    InvivoGen l ala γ d glu mdap
    Pre-treatment with NOD1- and NOD2-stimulatory ligands prior to infection with C. trachomatis significantly impacts inclusion size in NLR-expressing cell lines. HepG2, C-33A, and SiHa cells were pre-treated with <t>Tri-DAP,</t> MDP, or both, prior to infection with C. trachomatis L2 strain Bu/434. At 24 hpi, cells were fixed, inclusions were labeled, counted, and measured. zStacks of MOMP-labeled objects were obtained from a Zeiss 700 confocal microscope, and approximate volume measurements were calculated for all inclusions present within 10 imaging fields. Data presented represent all MOMP-labeled objects counted resulting in inclusions > 20 µm 3 ; 3 µm across with red lines indicating the mean of each group within a data set. Significance was assessed via one-way ANOVA with multiple comparisons. ****; P < 0.0001, ***; P < 0.001, **; P < 0.01, ns; not significant.
    L Ala γ D Glu Mdap, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/l ala γ d glu mdap/product/InvivoGen
    Average 94 stars, based on 1 article reviews
    l ala γ d glu mdap - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    lala γ d glu mdap  (InvivoGen)
    94
    InvivoGen lala γ d glu mdap
    Pre-treatment with NOD1- and NOD2-stimulatory ligands prior to infection with C. trachomatis significantly impacts inclusion size in NLR-expressing cell lines. HepG2, C-33A, and SiHa cells were pre-treated with <t>Tri-DAP,</t> MDP, or both, prior to infection with C. trachomatis L2 strain Bu/434. At 24 hpi, cells were fixed, inclusions were labeled, counted, and measured. zStacks of MOMP-labeled objects were obtained from a Zeiss 700 confocal microscope, and approximate volume measurements were calculated for all inclusions present within 10 imaging fields. Data presented represent all MOMP-labeled objects counted resulting in inclusions > 20 µm 3 ; 3 µm across with red lines indicating the mean of each group within a data set. Significance was assessed via one-way ANOVA with multiple comparisons. ****; P < 0.0001, ***; P < 0.001, **; P < 0.01, ns; not significant.
    Lala γ D Glu Mdap, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lala γ d glu mdap/product/InvivoGen
    Average 94 stars, based on 1 article reviews
    lala γ d glu mdap - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Pre-treatment with NOD1- and NOD2-stimulatory ligands prior to infection with C. trachomatis significantly impacts inclusion size in NLR-expressing cell lines. HepG2, C-33A, and SiHa cells were pre-treated with Tri-DAP, MDP, or both, prior to infection with C. trachomatis L2 strain Bu/434. At 24 hpi, cells were fixed, inclusions were labeled, counted, and measured. zStacks of MOMP-labeled objects were obtained from a Zeiss 700 confocal microscope, and approximate volume measurements were calculated for all inclusions present within 10 imaging fields. Data presented represent all MOMP-labeled objects counted resulting in inclusions > 20 µm 3 ; 3 µm across with red lines indicating the mean of each group within a data set. Significance was assessed via one-way ANOVA with multiple comparisons. ****; P < 0.0001, ***; P < 0.001, **; P < 0.01, ns; not significant.

    Journal: Infection and Immunity

    Article Title: Chlamydia trachomatis restricts signaling through NOD2 until late in the pathogen’s developmental cycle

    doi: 10.1128/iai.00472-25

    Figure Lengend Snippet: Pre-treatment with NOD1- and NOD2-stimulatory ligands prior to infection with C. trachomatis significantly impacts inclusion size in NLR-expressing cell lines. HepG2, C-33A, and SiHa cells were pre-treated with Tri-DAP, MDP, or both, prior to infection with C. trachomatis L2 strain Bu/434. At 24 hpi, cells were fixed, inclusions were labeled, counted, and measured. zStacks of MOMP-labeled objects were obtained from a Zeiss 700 confocal microscope, and approximate volume measurements were calculated for all inclusions present within 10 imaging fields. Data presented represent all MOMP-labeled objects counted resulting in inclusions > 20 µm 3 ; 3 µm across with red lines indicating the mean of each group within a data set. Significance was assessed via one-way ANOVA with multiple comparisons. ****; P < 0.0001, ***; P < 0.001, **; P < 0.01, ns; not significant.

    Article Snippet: MDP and L-Ala-γ-D-Glu-mDAP (Tri-DAP) were purchased from InvivoGen.

    Techniques: Infection, Expressing, Labeling, Microscopy, Imaging

    Pre-treatment with NOD2-stimulatory ligands delays the development of C. trachomatis in NLR-expressing cell lines. HepG2 ( A ), C-33A ( B ), and SiHa ( C ) cells were either left untreated or pre-treated with the NOD1-stimulatory ligand Tri-DAP, the NOD2-stimulatory ligand MDP, or both Tri-DAP and MDP. After 24 hours, cells were infected with C. trachomatis , and the development of infectious EBs was assessed at the indicated time points (30, 48, and 72 hpi). Lines delineate the mean of three separate biological replicates with each replicate displayed as a colored dot. Significance was assessed via one-way ANOVA with multiple comparisons. **; P < 0.01, *; P < 0.05, ns; not significant.

    Journal: Infection and Immunity

    Article Title: Chlamydia trachomatis restricts signaling through NOD2 until late in the pathogen’s developmental cycle

    doi: 10.1128/iai.00472-25

    Figure Lengend Snippet: Pre-treatment with NOD2-stimulatory ligands delays the development of C. trachomatis in NLR-expressing cell lines. HepG2 ( A ), C-33A ( B ), and SiHa ( C ) cells were either left untreated or pre-treated with the NOD1-stimulatory ligand Tri-DAP, the NOD2-stimulatory ligand MDP, or both Tri-DAP and MDP. After 24 hours, cells were infected with C. trachomatis , and the development of infectious EBs was assessed at the indicated time points (30, 48, and 72 hpi). Lines delineate the mean of three separate biological replicates with each replicate displayed as a colored dot. Significance was assessed via one-way ANOVA with multiple comparisons. **; P < 0.01, *; P < 0.05, ns; not significant.

    Article Snippet: MDP and L-Ala-γ-D-Glu-mDAP (Tri-DAP) were purchased from InvivoGen.

    Techniques: Expressing, Infection